Open AccessExploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital
Author(s) -
Lilian Bringolf,
Bernhard C. Pestalozzi,
Daniel Fink,
Konstantin J. Dedes
Publication year - 2016
Publication title -
schweizerische medizinische wochenschrift
Language(s) - English
Resource type - Journals
ISSN - 0036-7672
DOI - 10.4414/smw.2016.14393
Subject(s) - medicine , trastuzumab , breast cancer , metastatic breast cancer , oncology , retrospective cohort study , cohort , cancer , confidence interval
HER2-targeted treatment has improved the overall survival of patients with HER2-postive metastatic breast cancer with median OS exceeding 5 years. There are, however, no predictive markers for a long-term survival. Only the absence of primary brain metastases seems to be an indicator of a good prognosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom